236 related articles for article (PubMed ID: 37380971)
21. Differential expression of SLITRK6 gene as a potential therapeutic target for urothelial carcinoma in particular upper tract cancer.
Mir MA; Pandith AA; Mansoor S; Baba SM; Makhdoomi R; Ain QU; Anwar I; Para SA; Bhat AH; Koul AM; Manzoor U; Khan I; Beg A; Wani MS
Gene; 2023 Aug; 878():147583. PubMed ID: 37353040
[TBL] [Abstract][Full Text] [Related]
22. SERPINE2 Overexpression Is Associated with Poor Prognosis of Urothelial Carcinoma.
Chuang HW; Hsia KT; Liao JB; Yeh CC; Kuo WT; Yang YF
Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679626
[TBL] [Abstract][Full Text] [Related]
23. High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis.
Lai HY; Chiu CC; Kuo YH; Tsai HH; Wu LC; Tseng WH; Liu CL; Hsing CH; Huang SK; Li CF
Front Oncol; 2022; 12():834249. PubMed ID: 35372028
[TBL] [Abstract][Full Text] [Related]
24. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma.
Chan TC; Wu WJ; Li WM; Shiao MS; Shiue YL; Li CF
Theranostics; 2020; 10(25):11775-11793. PubMed ID: 33052246
[TBL] [Abstract][Full Text] [Related]
25. Necdin Overexpression Predicts Poor Prognosis in Patients with Urothelial Carcinomas of the Upper Urinary Tract and Urinary Bladder.
Chang IW; Wang YH; Wu WJ; Liang PI; Li WM; Yeh BW; Wu TF; He HL; Huang SK; Li CF
J Cancer; 2016; 7(3):304-13. PubMed ID: 26918044
[TBL] [Abstract][Full Text] [Related]
26. The metabolic syndrome is associated with the risk of urothelial carcinoma from a health examination database.
Lee HY; Tang JH; Chen YH; Wu WJ; Juan YS; Li WM; Chan TC
Int J Clin Oncol; 2021 Mar; 26(3):569-577. PubMed ID: 33231793
[TBL] [Abstract][Full Text] [Related]
27. EMP2 induces cytostasis and apoptosis via the TGFβ/SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma.
Li CF; Chan TC; Pan CT; Vejvisithsakul PP; Lai JC; Chen SY; Hsu YW; Shiao MS; Shiue YL
Cell Oncol (Dordr); 2021 Oct; 44(5):1133-1150. PubMed ID: 34339014
[TBL] [Abstract][Full Text] [Related]
28. Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.
Wu WR; Lin JT; Pan CT; Chan TC; Liu CL; Wu WJ; Sheu JJ; Yeh BW; Huang SK; Jhung JY; Hsiao MS; Li CF; Shiue YL
Theranostics; 2020; 10(2):707-724. PubMed ID: 31903146
[TBL] [Abstract][Full Text] [Related]
29. CDCA5 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
Chang IW; Lin VC; He HL; Hsu CT; Li CC; Wu WJ; Huang CN; Wu TF; Li CF
Am J Transl Res; 2015; 7(4):710-22. PubMed ID: 26064439
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of the cytochrome P450 4B1 protein confers a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
Lin JT; Chan TC; Li CF; Huan SKH; Tian YF; Liang PI; Pan CT; Shiue YL
APMIS; 2019 Apr; 127(4):170-180. PubMed ID: 30803053
[TBL] [Abstract][Full Text] [Related]
31. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer.
Kanda M; Nomoto S; Oya H; Shimizu D; Takami H; Hibino S; Hashimoto R; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
J Exp Clin Cancer Res; 2014 Aug; 33(1):66. PubMed ID: 25096402
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours.
Yates DR; Rouprêt M; Drouin SJ; Audouin M; Cancel-Tassin G; Comperat E; Bitker MO; Cussenot O
World J Urol; 2013 Feb; 31(1):53-9. PubMed ID: 23053209
[TBL] [Abstract][Full Text] [Related]
33. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
Yates DR; Catto JW
World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma.
Li J; Liang Y; Fan J; Xu C; Guan B; Zhang J; Guo B; Shi Y; Wang P; Tan Y; Zhang Q; Yuan C; Wu Y; Zhou L; Ci W; Li X
BMC Med; 2022 Jul; 20(1):222. PubMed ID: 35843958
[TBL] [Abstract][Full Text] [Related]
35. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor.
Oya H; Kanda M; Sugimoto H; Shimizu D; Takami H; Hibino S; Hashimoto R; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Nomoto S; Fujiwara M; Kodera Y
J Gastroenterol; 2015 May; 50(5):590-600. PubMed ID: 25173447
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
37. Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma.
Li CF; Shen KH; Huang LC; Huang HY; Wang YH; Wu TF
Pathology; 2010 Jan; 42(1):43-9. PubMed ID: 20025479
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
Wu K; Liu X; Wang Y; Wang X; Li X
Front Public Health; 2022; 10():994351. PubMed ID: 36388369
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression.
Chan TC; Hsing CH; Shiue YL; Huang SK; Hsieh KL; Kuo YH; Li CF
Cells; 2022 Feb; 11(4):. PubMed ID: 35203290
[TBL] [Abstract][Full Text] [Related]
40. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy.
Yeh HC; Margulis V; Singla N; Hernandez E; Panwar V; Woldu SL; Karam JA; Wood CG; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Li CC; Ke HL; Li WM; Lee HY; Rapoport LM; Lotan Y; Kapur P; Shariat SF; Hsieh JT; Wu WJ
Urol Oncol; 2020 May; 38(5):496-505. PubMed ID: 31862213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
